Hologic welcomes Dr. Martin Madaus to its Board of Directors

– USA, MA –  Hologic, Inc. (Nasdaq: HOLX) announced the election of Dr. Martin Madaus (Vet.D., Ph.D.) to its Board of Directors, effective December 6, 2024.

“We’re delighted to welcome Martin to Hologic’s Board of Directors,” said Chair,am and CEO, Steve MacMillan. “With his deep industry, technical, business and international experiences, Martin represents yet another strong addition to our deep and experienced Board.”

Dr. Madaus has also joined the Compensation Committee and the Nominating and Corporate Governance Committee.

About Dr. Martin Madaus

Dr. Madaus, who has more than 30 years of diagnostics and life sciences industry experience, currently serves as an Operating Executive at the Carlyle Group, a global investment firm, which he joined in February 2019. Before joining the Carlyle Group, Dr. Madaus held the role of Chairman and CEO at Ortho Clinical Diagnostics, Inc., a diagnostics company that makes products and diagnostic testing equipment for blood testing. Dr. Madaus previously served as the Chairman, President, and CEO of Milipore Corporation, a life sciences company serving the bioscience research and biopharmaceutical manufacturing industry, until its acquisition by Merck KGaA in 2010.

Dr. Madaus received a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

For more: https://www.hologic.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.